Inhibikase Therapeutics, Inc. Cash Flow Statement
IKT|4 years of annual SEC 10-K data (FY2021-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Inhibikase Therapeutics, Inc. used $18M in operating cash flow and negative free cash flow of $18M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Net Income | -$19.0M | -$18.1M | -$14.8M | -$2.8M |
| Depreciation & Amortization | $177.4K | $6.7K | $0 | - |
| Operating Cash Flow | -$18.1M | -$17.4M | -$14.3M | -$1.1M |
| Capital Expenditures | $14.2K | $243.3K | $0 | - |
| Free Cash Flow | -$18.1M | -$17.6M | -$14.3M | - |
| FCF Margin | -6947.9% | -14253.4% | -461.1% | - |